← All trials
NCT06946680
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2025
- Primary completion
- Dec 31, 2030
- Completion date
- Dec 31, 2045
- First posted
- Apr 27, 2025
- Last posted
- Oct 27, 2025
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of FloridaLead sponsor
- American Brain Tumor AssociationCollaborator
- St. Baldrick's FoundationCollaborator
- University of FloridaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.